LXRX Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2022-04-08 | 2021 | Brian T. Crum Senior Vice President and General Counsel | 407,609 | 135,450 | 219,975 | 0 | 14,429 | 1,288,353 |
| 2022-04-08 | 2020 | Brian T. Crum Senior Vice President and General Counsel | 387,747 | 136,986 | 208,828 | 0 | 12,192 | 1,209,201 |
| 2022-04-08 | 2019 | Brian T. Crum Senior Vice President and General Counsel | 369,287 | 133,072 | 246,825 | 0 | 11,955 | 932,885 |
| 2022-04-08 | 2021 | Craig B. Granowitz, M.D., Ph.D. | 188,322 | 73,175 | 0 | 0 | 646 | 948,548 |
| 2022-04-08 | 2021 | Lonnel Coats Chief Executive Officer and Director | 688,825 | 438,645 | 838,000 | 0 | 12,620 | 3,924,090 |
| 2022-04-08 | 2020 | Lonnel Coats Chief Executive Officer and Director | 668,620 | 473,188 | 840,376 | 0 | 12,420 | 3,860,671 |
| 2022-04-08 | 2019 | Lonnel Coats Chief Executive Officer and Director | 649,196 | 459,406 | 1,228,802 | 0 | 12,220 | 3,870,291 |
| 2022-04-08 | 2021 | Jeffrey L. Wade President and Chief Financial Officer | 476,319 | 227,250 | 280,981 | 0 | 14,574 | 1,651,683 |
| 2022-04-08 | 2020 | Jeffrey L. Wade President and Chief Financial Officer | 456,372 | 184,967 | 302,534 | 0 | 13,839 | 1,629,502 |
| 2022-04-08 | 2019 | Jeffrey L. Wade President and Chief Financial Officer | 444,431 | 181,817 | 491,488 | 0 | 12,116 | 1,614,323 |
| 2022-04-08 | 2019 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 393,270 | 140,542 | 421,336 | 0 | 11,730 | 1,395,440 |
| 2022-04-08 | 2020 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 403,824 | 144,406 | 231,369 | 0 | 11,945 | 1,305,309 |
| 2022-04-08 | 2021 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 414,024 | 148,016 | 225,673 | 0 | 12,158 | 1,323,864 |
| 2021-03-19 | 2019 | Praveen Tyle, Ph.D. Executive Vice President, Research and Development | 475,048 | 192,426 | 486,765 | 0 | 12,179 | 1,675,989 |
| 2021-03-19 | 2020 | Brian T. Crum Vice President and General Counsel | 387,747 | 136,986 | 208,828 | 0 | 12,192 | 1,209,201 |
| 2021-03-19 | 2018 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 436,644 | 158,450 | 280,630 | 0 | 11,895 | 1,408,003 |
| 2021-03-19 | 2019 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 444,431 | 181,817 | 491,488 | 0 | 12,116 | 1,614,323 |
| 2021-03-19 | 2020 | Praveen Tyle, Ph.D. Executive Vice President, Research and Development | 483,159 | 196,755 | 284,892 | 0 | 12,400 | 1,609,821 |
| 2021-03-19 | 2018 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 384,656 | 123,704 | 243,673 | 0 | 11,799 | 1,221,347 |
| 2021-03-19 | 2019 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 393,270 | 140,542 | 421,336 | 0 | 11,730 | 1,395,440 |
| 2021-03-19 | 2018 | Alexander A. Santini Former Executive Vice President and Chief | 399,719 | 102,501 | 248,568 | 0 | 11,828 | 1,233,219 |
| 2021-03-19 | 2019 | Alexander A. Santini Former Executive Vice President and Chief | 409,459 | 166,768 | 428,766 | 0 | 12,047 | 1,454,817 |
| 2021-03-19 | 2020 | Alexander A. Santini Former Executive Vice President and Chief | 315,075 | 0 | 233,554 | 0 | 286,765 | 1,354,036 |
| 2021-03-19 | 2018 | Pablo Lapuerta, M.D. Former Executive Vice President and Chief Medical | 401,482 | 121,646 | 251,701 | 0 | 11,827 | 1,259,810 |
| 2021-03-19 | 2019 | Pablo Lapuerta, M.D. Former Executive Vice President and Chief Medical | 410,487 | 148,387 | 438,209 | 0 | 12,046 | 1,458,562 |
| 2021-03-19 | 2020 | Pablo Lapuerta, M.D. Former Executive Vice President and Chief Medical | 317,070 | 0 | 272,777 | 0 | 667,349 | 1,862,885 |
| 2021-03-19 | 2020 | Alan J. Main, Ph.D. Executive Vice President, Innovation and Chemical | 403,824 | 144,406 | 231,369 | 0 | 11,945 | 1,305,309 |
| 2021-03-19 | 2018 | Brian T. Crum Vice President and General Counsel | 350,698 | 116,857 | 150,325 | 0 | 11,716 | 780,313 |
| 2021-03-19 | 2019 | Brian T. Crum Vice President and General Counsel | 369,287 | 133,072 | 246,825 | 0 | 11,955 | 932,885 |
| 2021-03-19 | 2018 | Praveen Tyle, Ph.D. Executive Vice President, Research and Development | 464,600 | 160,903 | 285,672 | 0 | 11,956 | 1,464,906 |
| 2021-03-19 | 2020 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 456,372 | 184,967 | 302,534 | 0 | 13,839 | 1,629,502 |
| 2021-03-19 | 2018 | Lonnel Coats President, Chief Executive Officer and Director | 634,159 | 402,399 | 690,587 | 0 | 12,020 | 3,123,433 |
| 2021-03-19 | 2019 | Lonnel Coats President, Chief Executive Officer and Director | 649,196 | 459,406 | 1,228,802 | 0 | 12,220 | 3,870,291 |
| 2021-03-19 | 2020 | Lonnel Coats President, Chief Executive Officer and Director | 668,620 | 473,188 | 840,376 | 0 | 12,420 | 3,860,671 |
| 2020-03-13 | 2017 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 427,038 | 154,963 | 161,584 | 0 | 11,675 | 1,214,435 |
| 2020-03-13 | 2018 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 436,644 | 158,450 | 280,630 | 0 | 11,895 | 1,408,003 |
| 2020-03-13 | 2019 | Lonnel Coats President, Chief Executive Officer and Director | 649,196 | 459,406 | 1,228,802 | 0 | 12,220 | 3,870,291 |
| 2020-03-13 | 2018 | Lonnel Coats President, Chief Executive Officer and Director | 634,159 | 402,399 | 690,587 | 0 | 12,020 | 3,123,433 |
| 2020-03-13 | 2017 | Lonnel Coats President, Chief Executive Officer and Director | 618,259 | 392,585 | 309,738 | 0 | 11,820 | 2,212,187 |
| 2020-03-13 | 2019 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 444,431 | 181,817 | 491,488 | 0 | 12,116 | 1,614,323 |
| 2018-03-16 | 2015 | Lonnel Coats President, Chief Executive Officer and Director | 561,835 | 439,912 | 270,021 | 0 | 720 | 2,099,433 |
| 2018-03-16 | 2016 | Alexander A. Santini Executive Vice President and Chief Commercial Officer | 313,572 | 162,000 | 77,162 | 0 | 11,051 | 702,917 |
| 2018-03-16 | 2015 | Alexander A. Santini Executive Vice President and Chief Commercial Officer | 201,434 | 58,000 | 0 | 0 | 5,353 | 328,935 |
| 2018-03-16 | 2017 | Lonnel Coats President, Chief Executive Officer and Director | 618,259 | 392,585 | 309,738 | 0 | 11,820 | 2,212,187 |
| 2018-03-16 | 2016 | Lonnel Coats President, Chief Executive Officer and Director | 597,568 | 444,675 | 275,192 | 0 | 6,770 | 2,174,646 |
| 2018-03-16 | 2017 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 427,038 | 154,963 | 161,584 | 0 | 11,675 | 1,214,435 |
| 2018-03-16 | 2016 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 416,783 | 182,393 | 147,436 | 0 | 11,202 | 1,213,604 |
| 2018-03-16 | 2015 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 401,227 | 238,108 | 144,710 | 0 | 7,205 | 1,234,431 |
| 2018-03-16 | 2017 | Pablo Lapuerta, M.D. Executive Vice President and Chief Medical Officer | 394,604 | 100,233 | 149,310 | 0 | 11,609 | 1,080,059 |
| 2018-03-16 | 2016 | Pablo Lapuerta, M.D. Executive Vice President and Chief Medical Officer | 385,949 | 144,400 | 138,662 | 0 | 11,158 | 1,108,716 |
| 2018-03-16 | 2015 | Pablo Lapuerta, M.D. Executive Vice President and Chief Medical Officer | 377,963 | 125,606 | 113,386 | 0 | 7,172 | 971,364 |
| 2018-03-16 | 2017 | Alexander A. Santini Executive Vice President and Chief Commercial Officer | 393,830 | 93,313 | 149,743 | 0 | 11,611 | 1,073,826 |
| 2018-03-16 | 2017 | Praveen Tyle, Ph.D. Executive Vice President, | 454,383 | 165,645 | 172,702 | 0 | 11,736 | 1,295,333 |
| 2018-03-16 | 2016 | Praveen Tyle, Ph.D. Executive Vice President, | 278,509 | 182,500 | 0 | 0 | 26,373 | 1,430,282 |
| 2016-03-18 | 2014 | Lonnel Coats President, Chief Executive | 266,901 | 165,006 | 0 | 0 | 300 | 1,531,430 |
| 2016-03-18 | 2014 | Alan J. Main, Ph.D. Executive Vice President, CMC and Supply Operations | 357,000 | 99,960 | 129,000 | 0 | 7,014 | 988,794 |
| 2016-03-18 | 2015 | Alan J. Main, Ph.D. Executive Vice President, CMC and Supply Operations | 360,967 | 121,344 | 131,360 | 0 | 7,152 | 1,023,117 |
| 2016-03-18 | 2013 | Pablo Lapuerta, M.D. Executive Vice President, and Chief Medical Officer | 370,000 | 0 | 146,300 | 0 | 6,904 | 968,852 |
| 2016-03-18 | 2014 | Pablo Lapuerta, M.D. Executive Vice President, and Chief Medical Officer | 375,000 | 70,350 | 135,880 | 0 | 7,040 | 1,005,200 |
| 2016-03-18 | 2015 | Pablo Lapuerta, M.D. Executive Vice President, and Chief Medical Officer | 377,963 | 125,606 | 113,386 | 0 | 7,172 | 971,364 |
| 2016-03-18 | 2015 | John P. Northcott | 312,383 | 0 | 107,330 | 0 | 26,071 | 774,485 |
| 2016-03-18 | 2015 | James F. Tessmer | 252,197 | 63,911 | 66,480 | 0 | 6,991 | 508,342 |
| 2016-03-18 | 2013 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 391,667 | 0 | 142,120 | 0 | 6,938 | 973,640 |
| 2016-03-18 | 2014 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 393,000 | 141,480 | 141,040 | 0 | 7,066 | 1,115,349 |
| 2016-03-18 | 2015 | Jeffrey L. Wade Executive Vice President, Corporate and Administrative | 401,227 | 238,108 | 144,710 | 0 | 7,205 | 1,234,431 |
| 2016-03-18 | 2013 | Alan J. Main, Ph.D. Executive Vice President, CMC and Supply Operations | 355,833 | 0 | 137,940 | 0 | 6,887 | 920,842 |
| 2016-03-18 | 2015 | Lonnel Coats President, Chief Executive | 561,835 | 439,912 | 270,021 | 0 | 720 | 2,099,433 |
| 2014-03-14 | 2011 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 400,000 | 115,000 | 201,350 | 0 | 6,701 | 1,194,257 |
| 2014-03-14 | 2013 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 391,667 | 0 | 142,120 | 0 | 6,938 | 973,640 |
| 2014-03-14 | 2012 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 385,000 | 100,000 | 140,400 | 0 | 6,804 | 1,059,176 |
| 2014-03-14 | 2011 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 385,000 | 105,000 | 170,750 | 0 | 6,679 | 1,083,199 |
| 2014-03-14 | 2013 | Pablo Lapuerta, M.D. Executive Vice President, Clinical Development and | 370,000 | 0 | 146,300 | 0 | 6,904 | 968,852 |
| 2014-03-14 | 2013 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 580,000 | 0 | 292,600 | 0 | 7,095 | 1,770,991 |
| 2014-03-14 | 2012 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 580,000 | 215,000 | 266,400 | 0 | 6,970 | 1,878,522 |
| 2014-03-14 | 2011 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 580,000 | 195,000 | 332,450 | 0 | 6,845 | 1,918,117 |
| 2014-03-14 | 2012 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 350,000 | 90,000 | 126,000 | 0 | 6,754 | 955,934 |
| 2014-03-14 | 2011 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 350,000 | 80,000 | 152,650 | 0 | 6,629 | 949,613 |
| 2014-03-14 | 2013 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 406,667 | 0 | 167,200 | 0 | 6,502 | 1,089,681 |
| 2014-03-14 | 2012 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 400,000 | 120,000 | 154,800 | 0 | 6,826 | 1,152,390 |
| 2014-03-14 | 2012 | Pablo Lapuerta, M.D. Executive Vice President, Clinical Development and | 345,000 | 100,000 | 93,600 | 0 | 6,747 | 829,995 |
| 2014-03-14 | 2011 | Pablo Lapuerta, M.D. Executive Vice President, Clinical Development and | 268,038 | 55,000 | 0 | 0 | 6,498 | 592,356 |
| 2014-03-14 | 2013 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 355,833 | 0 | 137,940 | 0 | 6,887 | 920,842 |
| 2013-03-25 | 2012 | Pablo Lapuerta, M.D. Executive Vice President, | 345,000 | 100,000 | 93,600 | 0 | 6,747 | 829,995 |
| 2013-03-25 | 2011 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 385,000 | 105,000 | 170,750 | 0 | 6,679 | 1,083,199 |
| 2013-03-25 | 2012 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 385,000 | 100,000 | 140,400 | 0 | 6,804 | 1,059,176 |
| 2013-03-25 | 2010 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 395,625 | 47,500 | 79,990 | 0 | 6,700 | 1,192,980 |
| 2013-03-25 | 2011 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 400,000 | 115,000 | 201,350 | 0 | 6,701 | 1,194,257 |
| 2013-03-25 | 2012 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 400,000 | 120,000 | 154,800 | 0 | 6,826 | 1,152,390 |
| 2013-03-25 | 2010 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 348,750 | 35,000 | 60,040 | 0 | 6,633 | 929,376 |
| 2013-03-25 | 2011 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 350,000 | 80,000 | 152,650 | 0 | 6,629 | 949,613 |
| 2013-03-25 | 2012 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 350,000 | 90,000 | 126,000 | 0 | 6,754 | 955,934 |
| 2013-03-25 | 2011 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 580,000 | 195,000 | 332,450 | 0 | 6,845 | 1,918,117 |
| 2013-03-25 | 2012 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 580,000 | 215,000 | 266,400 | 0 | 6,970 | 1,878,522 |
| 2013-03-25 | 2010 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 577,500 | 70,000 | 140,030 | 0 | 6,855 | 1,921,766 |
| 2013-03-25 | 2011 | Pablo Lapuerta, M.D. Executive Vice President, | 268,038 | 55,000 | 0 | 0 | 6,498 | 592,356 |
| 2013-03-25 | 2010 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 374,375 | 35,000 | 60,040 | 0 | 6,668 | 1,146,351 |
| 2012-03-16 | 2009 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 365,000 | 120,000 | 80,040 | 0 | 6,738 | 1,060,253 |
| 2012-03-16 | 2010 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 395,625 | 47,500 | 79,990 | 0 | 6,700 | 1,192,980 |
| 2012-03-16 | 2011 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 580,000 | 195,000 | 332,450 | 0 | 6,845 | 1,918,117 |
| 2012-03-16 | 2010 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 577,500 | 70,000 | 140,030 | 0 | 6,855 | 1,921,766 |
| 2012-03-16 | 2009 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 560,000 | 210,000 | 149,930 | 0 | 6,965 | 1,768,158 |
| 2012-03-16 | 2011 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 385,000 | 105,000 | 170,750 | 0 | 6,679 | 1,083,199 |
| 2012-03-16 | 2010 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 374,375 | 35,000 | 60,040 | 0 | 6,668 | 1,146,351 |
| 2012-03-16 | 2009 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 340,000 | 90,000 | 64,960 | 0 | 6,696 | 908,719 |
| 2012-03-16 | 2011 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 350,000 | 80,000 | 152,650 | 0 | 6,629 | 949,613 |
| 2012-03-16 | 2010 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 348,750 | 35,000 | 60,040 | 0 | 6,633 | 929,376 |
| 2012-03-16 | 2009 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 340,000 | 90,000 | 64,960 | 0 | 6,696 | 854,444 |
| 2012-03-16 | 2011 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 400,000 | 115,000 | 201,350 | 0 | 6,701 | 1,194,257 |
| 2012-03-16 | 2011 | Pablo Lapuerta, M.D. | 268,038 | 55,000 | 0 | 0 | 6,498 | 592,356 |
| 2011-03-18 | 2010 | Philip M. Brown, M.D., J.D. | 267,292 | 0 | 49,970 | 0 | 70,251 | 682,253 |
| 2011-03-18 | 2010 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 577,500 | 70,000 | 140,030 | 0 | 6,855 | 1,921,766 |
| 2011-03-18 | 2009 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 560,000 | 210,000 | 149,930 | 0 | 6,965 | 1,768,158 |
| 2011-03-18 | 2008 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 557,500 | 0 | 0 | 0 | 6,470 | 1,436,648 |
| 2011-03-18 | 2010 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 374,375 | 35,000 | 60,040 | 0 | 6,668 | 1,146,351 |
| 2011-03-18 | 2009 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 340,000 | 90,000 | 64,960 | 0 | 6,696 | 908,719 |
| 2011-03-18 | 2008 | Jeffrey L. Wade, J.D. Executive Vice President, Corporate Development and | 338,333 | 0 | 0 | 0 | 6,235 | 648,108 |
| 2011-03-18 | 2010 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 348,750 | 35,000 | 60,040 | 0 | 6,633 | 929,376 |
| 2011-03-18 | 2009 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 340,000 | 90,000 | 64,960 | 0 | 6,696 | 854,444 |
| 2011-03-18 | 2008 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 338,750 | 0 | 0 | 0 | 6,236 | 648,526 |
| 2011-03-18 | 2010 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 395,625 | 47,500 | 79,990 | 0 | 6,700 | 1,192,980 |
| 2011-03-18 | 2009 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 365,000 | 120,000 | 80,040 | 0 | 6,738 | 1,060,253 |
| 2011-03-18 | 2008 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 363,333 | 0 | 0 | 0 | 6,271 | 938,742 |
| 2011-03-18 | 2010 | Steven A. Tragash | 252,500 | 38,250 | 19,950 | 0 | 3,755 | 424,983 |
| 2011-03-18 | 2010 | Ajay Bansal Former Executive Vice President, | 7,846 | 0 | 0 | 0 | 333,616 | 341,462 |
| 2011-03-18 | 2009 | Ajay Bansal Former Executive Vice President, | 198,333 | 0 | 0 | 0 | 94,302 | 584,685 |
| 2011-03-18 | 2010 | James F. Tessmer Vice President, Finance and Accounting | 233,750 | 12,500 | 25,080 | 0 | 6,466 | 425,166 |
| 2011-03-18 | 2009 | James F. Tessmer Vice President, Finance and Accounting | 225,000 | 45,000 | 34,945 | 0 | 6,003 | 473,773 |
| 2011-03-18 | 2008 | James F. Tessmer Vice President, Finance and Accounting | 224,583 | 0 | 0 | 0 | 6,073 | 291,364 |
| 2010-03-19 | 2009 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 365,000 | 120,000 | 80,040 | 0 | 6,738 | 1,060,253 |
| 2010-03-19 | 2007 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 316,500 | 130,000 | 0 | 0 | 6,079 | 805,355 |
| 2010-03-19 | 2007 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 522,875 | 265,000 | 0 | 0 | 6,339 | 1,793,746 |
| 2010-03-19 | 2008 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 557,500 | 0 | 0 | 0 | 6,470 | 1,436,648 |
| 2010-03-19 | 2009 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 560,000 | 210,000 | 149,930 | 0 | 6,965 | 1,768,158 |
| 2010-03-19 | 2007 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 340,875 | 140,000 | 0 | 0 | 6,114 | 1,074,949 |
| 2010-03-19 | 2008 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 363,333 | 0 | 0 | 0 | 6,271 | 938,742 |
| 2010-03-19 | 2009 | Ajay Bansal | 198,333 | 0 | 0 | 0 | 94,302 | 584,685 |
| 2010-03-19 | 2009 | James F. Tessmer Vice President, Finance and | 225,000 | 45,000 | 34,945 | 0 | 6,003 | 473,773 |
| 2010-03-19 | 2008 | James F. Tessmer Vice President, Finance and | 224,583 | 0 | 0 | 0 | 6,073 | 291,364 |
| 2010-03-19 | 2008 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 338,333 | 0 | 0 | 0 | 6,235 | 648,108 |
| 2010-03-19 | 2009 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 340,000 | 90,000 | 64,960 | 0 | 6,696 | 908,719 |
| 2010-03-19 | 2007 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 323,375 | 130,000 | 0 | 0 | 6,090 | 753,445 |
| 2010-03-19 | 2008 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 338,750 | 0 | 0 | 0 | 6,236 | 648,526 |
| 2010-03-19 | 2009 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 340,000 | 90,000 | 64,960 | 0 | 6,696 | 854,444 |
| 2009-03-13 | 2007 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 323,375 | 130,000 | 0 | 0 | 6,090 | 704,098 |
| 2009-03-13 | 2008 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 338,333 | 0 | 30,569 | 0 | 6,235 | 690,424 |
| 2009-03-13 | 2007 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 316,500 | 130,000 | 0 | 0 | 6,079 | 779,546 |
| 2009-03-13 | 2006 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 292,000 | 80,000 | 0 | 0 | 5,920 | 668,595 |
| 2009-03-13 | 2008 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 363,333 | 0 | 37,666 | 0 | 6,271 | 886,418 |
| 2009-03-13 | 2007 | Julia P. Gregory Former Executive Vice President and Chief Financial Officer | 334,250 | 120,000 | 0 | 0 | 6,106 | 804,477 |
| 2009-03-13 | 2007 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 340,875 | 140,000 | 0 | 0 | 6,114 | 935,990 |
| 2009-03-13 | 2006 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 312,000 | 120,000 | 0 | 0 | 5,949 | 800,384 |
| 2009-03-13 | 2008 | James F. Tessmer | 224,583 | 0 | 16,445 | 0 | 6,073 | 290,831 |
| 2009-03-13 | 2008 | Julia P. Gregory Former Executive Vice President and Chief Financial Officer | 115,417 | 0 | 0 | 0 | 350,461 | 749,378 |
| 2009-03-13 | 2008 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 557,500 | 0 | 70,555 | 0 | 6,470 | 1,534,809 |
| 2009-03-13 | 2007 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 522,875 | 265,000 | 0 | 0 | 6,339 | 1,703,056 |
| 2009-03-13 | 2006 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 473,000 | 300,000 | 0 | 0 | 373,466 | 1,938,733 |
| 2009-03-13 | 2008 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 338,750 | 0 | 30,569 | 0 | 6,236 | 620,498 |
| 2009-03-13 | 2006 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 312,000 | 90,000 | 0 | 0 | 5,949 | 628,052 |
| 2009-03-13 | 2006 | Julia P. Gregory Former Executive Vice President and Chief Financial Officer | 329,000 | 80,000 | 0 | 0 | 5,974 | 747,142 |
| 2008-03-14 | 2006 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 292,000 | 80,000 | 0 | 0 | 5,920 | 668,595 |
| 2008-03-14 | 2007 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 323,375 | 130,000 | 0 | 0 | 6,090 | 704,098 |
| 2008-03-14 | 2006 | Julia P. Gregory Executive Vice President and Chief Financial Officer | 329,000 | 80,000 | 0 | 0 | 5,974 | 747,142 |
| 2008-03-14 | 2007 | Julia P. Gregory Executive Vice President and Chief Financial Officer | 334,250 | 120,000 | 0 | 0 | 6,106 | 804,477 |
| 2008-03-14 | 2007 | Jeffrey L. Wade, J.D. Executive Vice President and General Counsel | 316,500 | 130,000 | 0 | 0 | 6,079 | 779,546 |
| 2008-03-14 | 2006 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 473,000 | 300,000 | 0 | 0 | 373,466 | 1,938,733 |
| 2008-03-14 | 2007 | Arthur T. Sands, M.D., Ph.D. President, Chief Executive Officer and Director | 522,875 | 265,000 | 0 | 0 | 6,339 | 1,703,056 |
| 2008-03-14 | 2006 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 312,000 | 120,000 | 0 | 0 | 5,949 | 800,384 |
| 2008-03-14 | 2007 | Brian P. Zambrowicz, Ph.D. Executive Vice President and Chief Scientific Officer | 340,875 | 140,000 | 0 | 0 | 6,114 | 935,990 |
| 2008-03-14 | 2006 | Alan J. Main, Ph.D. Executive Vice President of Pharmaceutical Research | 312,000 | 90,000 | 0 | 0 | 5,949 | 628,052 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
